Novo Nordisk publishes positive Wegovy heart failure data
The results show that Wegovy reduces symptoms in obese patients with diabetes and heart failure, or heart failure with preserved pump function.
by MARKETWIRE
Novo Nordisk has published positive results from a large study of its weight loss drug Wegovy in obese people with type 2 diabetes and heart failure with preserved pump function, Bloomberg News reports.
On Saturday, the New England Journal of Medicine published the year-long study showing that Wegovy reduces symptoms in obese patients with diabetes and heart failure with preserved pump function.
Novo Nordisk announced in its annual report back in January that the results from the study were positive.
Typical symptoms for patients with heart failure are shortness of breath and fatigue, especially during exertion.
(Translated using DeepL with additional editing by Catherine Brett)
